Vaccination Prior To COVID-19 Infection Provided 60% Protection Against Post-Discharge Mortality: ICMR Research Study

New Delhi : The study on factors related to the post-discharge one-year mortality among hospitalized COVID-19 patients study conducted by the Indian Council of Medical Research (ICMR) has revealed that vaccination prior to the COVID-19 infection (at least a single dose) provided 60 percent protection against post-discharge mortality. The study read,

“The study found a higher chance of dying within one year after discharge in males, those more than 40 years of age, those with comorbidities and those who had moderate-severe COVID disease to begin with. Vaccination prior to the COVID-19 infection (at least a single dose) provided 60% protection against post-discharge mortality. Similar trends were seen in participants, 18-45 years of age.”

It is worth mentioning that these results relate to patients who had been hospitalized during their initial COVID-19 infection and cannot be generalized to all COVID-19 patients.

The study conducted by the National Clinical Registry for Covid-19 team has evaluated the factors related to one-year post-discharge mortality. It said,

“National Clinical Registry for COVID-19 study team has conducted nested matched case-control analyses to evaluate the factors related to one-year post-discharge mortality.”

ICMR has been maintaining the National Clinical Registry for COVID-19 at 31 centres across the country, where all hospitalized COVID-19 patients were periodically contacted by telephone till one year after discharge. Data collected till February 2023 were included in this analysis.

According to the study,

“It was observed that of the 14,419 participants contacted at least once in one year after discharge from hospital, 942 (6.5%) all-cause mortality was reported. A nested matched case-control analysis was conducted to evaluate the factors related to one-year post-discharge mortality.”

ICMR is conducting more such studies like the Effect of the COVID-19 vaccine on thrombotic (blood clot within the blood vessels restricting the flow of blood) events among the 18–45-year-old population in India, 2022, said the Multicentric hospital-based matched case-control study.

Related Posts

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

New Delhi: The entry of semaglutide generics in India is ‘stimulating’ market growth and providing a favourable push to Eli Lilly’s blockbuster brand Mounjaro (tirzepatide), said Patrik Jonsson, Executive Vice…

Pak-made illegal cosmetics recovered from Itwari shop

Nagpur: Maharashtra Food and Drug Administration (FDA), Nagpur Division, raided a cosmetics firm in Itwari market and seized Pakistan-origin beauty products suspected to have harmful mercury and steroids last week. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Pak-made illegal cosmetics recovered from Itwari shop

Pak-made illegal cosmetics recovered from Itwari shop

Licences of 20 medical stores suspended after inspections

Licences of 20 medical stores suspended after inspections

Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

Bain Capital sells nearly 1 pc  stake in Emcure Pharma for Rs 289 crore

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

HP accounts for 47 inferior drugs in March alert

HP accounts for 47 inferior drugs in March alert